16.62
Precedente Chiudi:
$16.31
Aprire:
$16.31
Volume 24 ore:
1.93M
Relative Volume:
0.75
Capitalizzazione di mercato:
$2.10B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-8.2277
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
+0.79%
1M Prestazione:
-7.36%
6M Prestazione:
+27.75%
1 anno Prestazione:
+17.12%
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
TXG
10 X Genomics Inc
|
16.62 | 2.06B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
219.49 | 36.69B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
62.36 | 10.51B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
43.29 | 8.34B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
91.07 | 7.83B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
38.40 | 6.75B | 11.99B | 24.18M | 234.31M | 0.2956 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-12-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Iniziato | Piper Sandler | Neutral |
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
10x Genomics (TXG) Stock Is Up, What You Need To Know - Finviz
Financial Consulate Inc. Acquires New Holdings in 10x Genomics $TXG - MarketBeat
Weekly Earnings: Is 10x Genomics Inc 1KJ stock a top pick for value investorsWeekly Investment Report & Low Drawdown Trading Strategies - moha.gov.vn
S P Trends: How dovish Fed policy supports 10x Genomics Inc 1KJ stockMarket Sentiment Review & Weekly Watchlist of Top Performers - moha.gov.vn
10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Barchart.com
10x Genomics' Products Are Well-Received, But US Spending Weakness Stifles Growth (NASDAQ:TXG) - Seeking Alpha
Osaic Holdings Inc. Has $1.89 Million Stock Position in 10x Genomics $TXG - MarketBeat
Assenagon Asset Management S.A. Sells 1,696,984 Shares of 10x Genomics $TXG - MarketBeat
Friedenthal Financial Purchases New Holdings in 10x Genomics $TXG - MarketBeat
10x Genomics (NASDAQ:TXG) Trading Down 4.1%Should You Sell? - MarketBeat
Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending - Finviz
Barclays turns more bullish on 10x Genomics, Inc. (TXG) despite uneven research spending - MSN
Canaccord Genuity Maintains 10x Genomics (TXG) Buy Recommendation - Nasdaq
10x Genomics (TXG) Stock Trades Up, Here Is Why - Finviz
10x Genomics (TXG) Maintains Buy Rating, Price Target Raised to $20 | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Given New $20.00 Price Target at Canaccord Genuity Group - MarketBeat
Why 10x Genomics Inc. stock could outperform in 20252025 Price Targets & Fast Entry Momentum Trade Alerts - Улправда
How 10x Genomics Inc. stock responds to policy changesWall Street Watch & Weekly High Conviction Trade Ideas - ulpravda.ru
Aug Swings: Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumQuarterly Trade Summary & AI Driven Stock Movement Reports - Улправда
Price Action: Is 10x Genomics Inc. stock safe for conservative investorsJuly 2025 Opening Moves & Weekly Breakout Watchlists - Улправда
Is 10x Genomics Inc. stock safe for conservative investorsJuly 2025 Decliners & Consistent Income Trade Ideas - Улправда
Is 10x Genomics Inc. (1KJ) stock attractive for growth fundsJuly 2025 Movers & Free High Accuracy Swing Entry Alerts - Улправда
Can 10x Genomics Inc. (1KJ) stock sustain breakout momentumJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - Улправда
What technical charts say about 10x Genomics Inc. stockJuly 2025 Summary & Free Real-Time Volume Trigger Notifications - DonanımHaber
Panic Selling: How 10x Genomics Inc. stock responds to policy changesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - Улправда
Lancaster Investment Management Purchases Shares of 621,779 10x Genomics $TXG - MarketBeat
How 10x Genomics Inc. stock benefits from strong dollarWeekly Stock Summary & Comprehensive Market Scan Insights - DonanımHaber
Is 10x Genomics Inc. stock oversold or undervaluedJuly 2025 Recap & Daily Oversold Bounce Ideas - DonanımHaber
Why 10x Genomics Inc. stock could benefit from AI revolutionEntry Point & Short-Term Trading Alerts - Улправда
Is 10x Genomics Inc. stock a safe haven assetQuarterly Performance Summary & Technical Confirmation Alerts - DonanımHaber
History Review: Why 10x Genomics Inc. stock could outperform in 2025 - Улправда
Aug Rallies: Can 10x Genomics Inc. stock weather global recession2025 Winners & Losers & Low Risk High Reward Ideas - Улправда
Can 10x Genomics Inc. stock weather global recessionMarket Activity Report & Growth Focused Investment Plans - Улправда
Bear Alert: Why 10x Genomics Inc. stock could benefit from AI revolutionQuarterly Earnings Summary & Weekly Chart Analysis and Guides - Улправда
Setup Watch: Is 10x Genomics Inc. stock safe for conservative investors2025 Major Catalysts & Weekly Top Gainers Trade List - Улправда
Market Fear: How 10x Genomics Inc. stock responds to policy changesShare Buyback & Low Risk Growth Stock Ideas - Улправда
Barclays Maintains 10x Genomics (TXG) Overweight Recommendation - Nasdaq
Caxton Associates LLP Sells 259,388 Shares of 10x Genomics $TXG - MarketBeat
10x Genomics (NASDAQ:TXG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
10x Genomics $TXG Position Increased by Nikko Asset Management Americas Inc. - MarketBeat
Why The Narrative Around 10x Genomics Is Shifting After New Institutional Buying And Product Updates - Yahoo Finance
Bellevue Group AG Buys 95,754 Shares of 10x Genomics $TXG - MarketBeat
Federated Hermes Inc. Has $9.12 Million Holdings in 10x Genomics $TXG - MarketBeat
Why 10x Genomics (TXG) stock is nosediving - MSN
TXG: Citigroup Downgrades 10x Genomics to Neutral with $18 Price Target | TXG Stock News - GuruFocus
10x Genomics (TXG) Q2 2025 Earnings Transcript - The Motley Fool
10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off - ts2.tech
Why 10x Genomics (TXG) Stock Is Nosediving - Finviz
10x Genomics' (TXG) Neutral Rating Reaffirmed at Citigroup - MarketBeat
Citigroup Downgrades 10x Genomics to Neutral From Buy, Price Target is $18 - marketscreener.com
Blue Water Life Science Advisors LP Buys New Holdings in 10x Genomics $TXG - MarketBeat
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):